Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc.

2.99
EUR
-0.06
(-1.97%)
-1.65EPS
Mar 04Next Earn

Important Dates

Verrica Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for March 4, 2027.

Earnings Date3/4/2027

Share Statistics

As of June 30, 2026, Verrica Pharmaceuticals Inc. has 17.18M shares outstanding.

Shares Outstanding17.18M

Financial Position

As of June 30, 2026, Verrica Pharmaceuticals Inc. maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.02, indicating elevated leverage, while an interest coverage ratio of -7.40 demonstrates limited ability to service its debt obligations.

Current Ratio1.45
Quick Ratio0.99
Debt / Equity42.02
Debt / EBITDA-0.07
Interest Coverage-7.40

Financial Efficiency

EUR

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -83.02, reflecting losses generated across the asset base. The company generates approximately 355,049.78 in revenue per employee across its workforce of 74.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.63 indicates how many times Verrica Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-83.02
Revenue Per Employee355,049.78
Employee Count74.75
Inventory Turnover1.63

Income Statement

EUR

Over the twelve months ended June 30, 2026, Verrica Pharmaceuticals Inc. generated 26.54M in revenue and converted that into -27.29M in net income, yielding earnings per share of -1.65. EBITDA reached -24.16M, while operating income came in at -23.14M.

Revenue26.54M
Gross Profit22.80M
Operating Income-23.14M
Pretax Income-27.29M
Net Income-27.29M
EBITDA-24.16M
EBIT-24.84M
Earnings Per Share (EPS)-1.65

Balance Sheet

EUR

As of June 30, 2026, Verrica Pharmaceuticals Inc. holds 9.80M in cash and equivalents against 1.58M in total debt, resulting in a net debt position of -9.80M. Total book value stands at 3.77M, with working capital of 8.93M providing operational flexibility.

Cash & Cash Equivalents9.80M
Total Debt1.58M
Net Debt-9.80M
Equity (Book Value)3.77M
Book Value Per Share0.22
Working Capital8.93M

Cash Flow

EUR

Verrica Pharmaceuticals Inc. produced -11.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -11.68M - equivalent to -0.71 per share.

Operating Cash Flow-11.68M
Free Cash Flow-11.68M
FCF Per Share-0.71

Margins

Over the twelve months ended June 30, 2026, Verrica Pharmaceuticals Inc. posted a gross margin of 85.89, reflecting its pricing power and cost economics. The operating margin of -87.18 and net profit margin of -102.84 provide insight into operational efficiency.

Gross Margin85.89
Operating Margin-87.18
Pretax Margin-102.84
Profit Margin-102.84
EBITDA Margin-91.03

Stock Splits

Verrica Pharmaceuticals Inc.'s most recent stock split took place on July 25, 2025 with a 10:1 split ratio.

Last Split Date7/25/2025
Split Ratio10:1